1. Home
  2. THM vs CBIO Comparison

THM vs CBIO Comparison

Compare THM & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Tower Hill Mines Ltd. (Canada)

THM

International Tower Hill Mines Ltd. (Canada)

HOLD

Current Price

$2.05

Market Cap

685.5M

Sector

N/A

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$18.34

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
THM
CBIO
Founded
1978
2003
Country
Canada
United States
Employees
N/A
44
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
685.5M
557.8M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
THM
CBIO
Price
$2.05
$18.34
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
827.5K
242.3K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$279.20
P/E Ratio
$189.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$8.72
52 Week High
$3.65
$27.41

Technical Indicators

Market Signals
Indicator
THM
CBIO
Relative Strength Index (RSI) 35.87 48.69
Support Level $1.89 $16.31
Resistance Level $2.06 $21.60
Average True Range (ATR) 0.16 1.78
MACD -0.07 -0.20
Stochastic Oscillator 13.09 36.39

Price Performance

Historical Comparison
THM
CBIO

About THM International Tower Hill Mines Ltd. (Canada)

International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: